|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 报告非药物随机对照临床试验的CONSORT扩展声明:说明与详述(一)显示文摘正确报告随机对照临床试验(randomized controlled trial,RCT)是严格评价试验结果真实性与有效性的必要前提。含22项条目清单和流程图的CONSORT(Consolidated Standards of Reporting Trials)声明旨在通过改进RCT的报告来解决这一问题。然而,《CONSORT声明》中没有专门论及那些适用于非药物治疗(如手术、技术干预、仪器设备、康复理疗、心理治疗和行为干预等)临床试验的具体问题。此外,相当多的证据表明非药物临床试验的报告仍然需要改进,因此CONSORT小组针对评估非药物治疗的临床INFORMATION FOR AUTHORS试验制定了《CONSORT扩展声明》。为制定《CONSORT扩展声明》以规范非药物临床试验的报告,33名专家于2006年2月在法国巴黎组织召开了讨论会议,并就此达成了共识。与会者扩充了原有《CONSORT声明》中的11项条目,新增了1项条目,修改并重新制定了报告流程图。为便于充分理解和执行《CONSORT扩展声明》,CONSORT小组通过对文献的回顾编制了这一说明与详述文本,旨在为正确报告非药物临床试验提供范例。本扩展声明,连同《CONSORT声明》以及《CONSORT声明》的其他扩展本,将有助于改进非药物治疗领域RCT的报告。 | Isabelle Boutron David Moher Douglas G. Alt man Kenneth F. Schulz Philippe Ravaud | 2009 | 中西医结合学报2009，7，5： | 4 |
| 2 | Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial显示文摘 | Bernard Escudier Anna Pluzanska Piotr Koralewski Alain Ravaud Sergio Bracarda Cezary Szczylik Christine Chevreau Marek Filipek Bohuslav Melichar Emilio Bajetta Vera Gorbunova Jacques-Olivier Bay Istvan Bodrogi Agnieszka Jagiello-Gruszfeld Nicola Moore | 2007 | The Lancet . 2007 (9605)2007，，： | 2 |
| 3 | Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial显示文摘 | Robert J Motzer Bernard Escudier Stéphane Oudard Thomas E Hutson Camillo Porta Sergio Bracarda Viktor Grünwald John A Thompson Robert A Figlin Norbert Hollaender Gladys Urbanowitz William J Berg Andrea Kay David Lebwohl Alain Ravaud | 2008 | The Lancet2008，，9637： | 2 |
| 4 | Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy:The three-year prospective french research axed on tolerance of biotherapies registry显示文摘 | Tubach F Salmon D Ravaud P etal | 2009 | Arthritis Rheum2009，60，7： | 1 |
| 5 | Overexpression,purification,crystallization and preliminary diffraction studies of the Protaminobacter rubrum sucrose isomerase SmuA显示文摘 | Ravaud S Watzlawick H Haser R | 2006 | Acta Crystallographica2006，62，： | 1 |
| 6 | Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy 显示文摘 | TUBACH F SALMON D RAVAUD P | 2009 | Arthritis Rheum2009，60，7： | 1 |
| 7 | Safety and efficacy of rituximab in systemic lupus erythematosus:results from 136 patients from the French AutoImmunity and Rituximab registry显示文摘 | Terrier B Amoura Z Ravaud P | 2010 | Arthritis Rheum2010，62，： | 1 |
| 8 | Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-alpha treatments in cancer patients显示文摘 | Capuron L Ravaud A Dantzer R | 2001 | Psychosom Med2001，63，3： | 1 |
| 9 | Efficacy of rituximabin primary Sjogren's syndrome with peripheral nervous systeminvolvement: results from the AIR registry显示文摘 | Mekinian A Ravaud P Hatron PY | 2012 | Ann Rheum Dis2012，71，1： | 1 |
| 10 | UFT and leucovorin in first-line chemotherapy for patients with metastatic gastric cancer显示文摘 | Ravaud A Borner M Schellens J H | 2001 | Eur J Cancer2001，37，13： | 1 |
| 11 | Randomized clinical trial to asess the effect of an educational program designed to improve nurses' assessment and recording of postoperative pain 显示文摘 | Ravaud P Keita H Procher R | 2004 | British Journal of Surgery2004，91，： | 1 |
| 12 | EULAR Sjogren's syn- drome disease activity index: development of a consensus sys- temic disease activity index for primary Sjogren's syndrome显示文摘 | Seror R Ravaud P Bowman SJ | 2010 | Ann Rheum Dis2010，69，： | 1 |
| 13 | Sequential sorafenib and sunitinib for renal cell carcinoma显示文摘 | Sablin M P Negrier S Ravaud A | 2009 | J Urol2009，182，1： | 1 |
| 14 | Medroxyprogeste- rone,interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results from a randomized controlled trial 显示文摘 | Negrier S Perol D Ravaud C | 2007 | Cancer2007，110，11： | 1 |
| 15 | Mechanical properties of ferrofluid applications:Centering effect and capacity of a seal显示文摘 | Ravaud R Lemarquand G Lemarquand V | 2010 | Tribology International2010，43，： | 1 |
| 16 | Les thérapeutiques ciblées du cancer de vessie localement avancé et/ou métastatique显示文摘 | H. Wallerand G. Robert J.-C. Bernhard A. Ravaud J.-M. Ferrière | 2008 | Progres en Urologie2008，，7： | 1 |
| 17 | Maintenance of infliximab treatment in ankylosing sondylitis results of a one- year randomized controlled trial comparing systematic versus on-demand treatment显示文摘 | Breban M Ravaud P Claudepierre P | 2008 | Arthritis Rheum2008，58，1： | 1 |
| 18 | Efficacy of lapatinib in patients with high tumor EGFR expression: Results of a phase III trial in advanced renal cell carcinoma(RCC) 显示文摘 | RAVAUD A GARDNER J HAWKINS R | 2006 | J Clin Oncol2006，24，： | 1 |
| 19 | Risk of tuberculosis is higher with anti tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French research axed on tolerance of biotherapies registry显示文摘 | Tubach F Salmon D Ravaud P etal | 2009 | Arthritis Rheum2009，60，7： | 1 |
| 20 | Survival after bilateral versus single-lung transplantation for idiopathic pulmonary fibrosis显示文摘 | Thabut G Christie JD Ravaud P | 2009 | Ann Intern Med2009，151，11： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员